Douglas, Australia Clinical Trials

A listing of Douglas, Australia clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 24 clinical trials
Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

This study is designed to assess the safety and efficacy of lenvatinib in combination with pembrolizumab versus standard of care (SOC) chemotherapy, and to also assess the safety and efficacy of lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum …

metastatic head and neck squamous cell carcinoma
carcinoma
cetuximab
paclitaxel
monoclonal antibodies
Greenslopes Private Hospital ( Site 0105)
 (689.4 away) Contact site
  • 0 views
  • 25 Nov, 2020
  • +25 other locations
Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract Cancer

This is a multicenter, prospective, randomized, controlled phase III trial designed to assess the clinical performance of gemcitabine with cisplatin and observation vs. standard of care (observation alone in stage 1 and capecitabine and observation in stage 2) in patients after curative intent resection of BTC including an embedded sub-study …

gallbladder carcinoma
biliary disease
cisplatin/gemcitabine
cancer
biliary tract cancer
Royal Brisbane and Women's Hospital
 (684.9 away) Contact site
  • 458 views
  • 01 Oct, 2020
  • +68 other locations
A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

A study designed to evaluate the safety and efficacy of venetoclax plus dexamethasone (VenDex) compared with pomalidomide plus dexamethasone (PomDex) in participants with t(11;14)-positive Relapsed or Refractory Multiple Myeloma.

lenalidomide
pomalidomide
refractory multiple myeloma
dexamethasone
measurable disease
Icon Cancer Care - Townsville /ID# 206565
 (3.9 away) Contact site
  • 91 views
  • 25 Nov, 2020
  • +219 other locations
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

This study will evaluate the efficacy of uproleselan (GMI-1271), a specific E-selectin antagonist, in combination with chemotherapy to treat relapsed/refractory AML, compared to chemotherapy alone. The safety of uproleselan when given with chemotherapy will also be investigated in patients with relapsed/refractory AML

refractory acute myeloid leukemia (aml)
Princess Alexandra Hospital
 (687.2 away) Contact site
  • 89 views
  • 21 Nov, 2020
  • +53 other locations
Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

ICON 9 will assess the efficacy, safety and tolerability of maintenance olaparib in combination with cediranib compared to maintenance olaparib alone following a response to platinum-based chemotherapy in women with relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer. Prognostic and predictive factors will be studied from tumour and blood samples.

carcinoma
fallopian tube
peritoneal cancer
bevacizumab
tumor debulking
Townsville Hospital
 (5.8 away) Contact site
  • 392 views
  • 16 Sep, 2020
  • +40 other locations
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC MK-7339-008/KEYLYNK-008)

The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance olaparib placebo with respect to progression-free survival (PFS) per RECIST 1.1 by …

Townsville General Hospital ( Site 1202)
 (5.8 away) Contact site
  • 119 views
  • 22 Nov, 2020
  • +191 other locations
Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006 KEYLYNK-006)

The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, v.s. pembrolizumab plus maintenance pemetrexed for the treatment of nonsquamous NSCLC. The study's 2 primary hypotheses are: 1. Pembrolizumab plus maintenance olaparib is superior to pembrolizumab plus maintenance pemetrexed with respect to progression-free survival (PFS) per Response Evaluation Criteria in …

Townsville General Hospital ( Site 1202)
 (5.8 away) Contact site
  • 183 views
  • 19 Nov, 2020
  • +196 other locations
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

This trial will study ladiratuzumab vedotin (LV) to find out if it works to treat different types of solid tumors. It will also find out what side effects may occur. A side effect is anything the drug does besides treating cancer.

extensive disease
erbb2
chemoradiotherapy
cancer
adenocarcinoma
St Vincents Hospital Sydney
 (1037.7 away) Contact site
  • 12 views
  • 28 Oct, 2020
  • +42 other locations
Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

NuTide:121 compares NUC-1031 with gemcitabine, both in combination with cisplatin, in patients with previously untreated advanced biliary tract cancer. The primary hypotheses are: The combination of NUC-1031 plus cisplatin prolongs overall survival compared to the gemcitabine plus cisplatin standard of care The combination of NUC-1031 plus cisplatin increases overall response …

aptt
platelet count
cisplatin/gemcitabine
international normalized ratio
adenocarcinoma
Townsville Cancer Centre
 (2.4 away) Contact site
  • 73 views
  • 20 Jul, 2020
  • +84 other locations
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

The purpose of this study is to evaluate the efficacy and safety of Tislelizumab as first line treatment in combination with chemotherapy in participants with advanced unresectable/metastatic ESCC.

carcinoma
fluorouracil
paclitaxel
capecitabine
squamous cell carcinoma
Coffs Harbour Hospital
 (852.9 away) Contact site
  • 24 views
  • 23 Sep, 2020
  • +204 other locations